clinical trial · NCT06886009
Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis
Boehringer Ingelheim·—·withdrawn
Generalized Pustular PsoriasisSpevigo®
brief summary
The primary and secondary objectives are to respectively monitor the safety and effectiveness of Spesolimab IV in Korean patients with flares with generalized pustular psoriasis (GPP) in a routine medical practice.
started
Mar 31, 2026
primary completion
Jun 8, 2029
completion
Jun 8, 2029
last updated
Mar 31, 2026
official title
A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Spesolimab in Korean Patients With Flares With Generalized Pustular Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol